161 related articles for article (PubMed ID: 24681934)
1. [Recommendation for the optimal use of bendamustine in Japan].
Ohmachi K; Maruyama D; Nisikori M; Suzuki T; Izutsu K
Rinsho Ketsueki; 2014 Mar; 55(3):311-20. PubMed ID: 24681934
[No Abstract] [Full Text] [Related]
2. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
3. [Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy].
Mitsumori T; Sueki Y; Kawashima I; Yamamoto T; Nozaki Y; Nakajima K; Kirito K
Rinsho Ketsueki; 2014 Feb; 55(2):239-43. PubMed ID: 24598192
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab.
Warsch S; Hosein PJ; Morris MI; Teomete U; Benveniste R; Chapman JR; Lossos IS
Int J Hematol; 2012 Aug; 96(2):274-8. PubMed ID: 22684926
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series.
Parker SM; Hyder MA; Fesler MJ
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e15-7. PubMed ID: 24060287
[No Abstract] [Full Text] [Related]
8. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
9. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Matsumoto Y; Kobayashi T; Shimura Y; Kawata E; Nagoshi H; Ohshiro M; Sugitani M; Shimura K; Iwai T; Fuchida SI; Yoshida M; Kiyota M; Mizutani S; Chinen Y; Takimoto-Shimomura T; Nakao M; Kaneko H; Uchiyama H; Uoshima N; Nishigaki H; Kobayashi Y; Horiike S; Shimazaki C; Taniwaki M; Kuroda J;
Int J Hematol; 2019 Jul; 110(1):77-85. PubMed ID: 31127456
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
Higo T; Miyagaki T; Nakamura F; Shinohara A; Asano H; Abe H; Senda N; Yoshizaki A; Fukayama M; Kurokawa M
Ann Hematol; 2015 Apr; 94(4):683-5. PubMed ID: 25199505
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
12. Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
Waldthaler C; Stauder R; Schnallinger M; Schreieck S; Hager J; Oexle H; Zangerl G; Verdorfer I; Zabernigg A; Gastl G; Fiegl M
Wien Klin Wochenschr; 2011 May; 123(9-10):269-75. PubMed ID: 21479652
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine and rituximab is effective and cost-effective in older cases with aggressive lymphomas?
Paydas S
Ann Oncol; 2011 Dec; 22(12):2694-2695. PubMed ID: 21989331
[No Abstract] [Full Text] [Related]
14. Severe cutaneous interface drug eruption associated with bendamustine.
Alamdari HS; Pinter-Brown L; Cassarino DS; Chiu MW
Dermatol Online J; 2010 Jul; 16(7):1. PubMed ID: 20673529
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Hitz F; Fischer N; Pabst T; Caspar C; Berthod G; Eckhardt K; Berardi Vilei S; Zucca E; Mey U;
Ann Hematol; 2013 Aug; 92(8):1033-40. PubMed ID: 23592273
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Darwish M; Burke JM; Hellriegel E; Robertson P; Phillips L; Ludwig E; Munteanu MC; Bond M
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1119-27. PubMed ID: 24677018
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
Gopal AK; Tarantolo SR; Bellam N; Green DJ; Griffin M; Feldman T; Mato AR; Eisenfeld AJ; Stromatt SC; Goy A
Invest New Drugs; 2014 Dec; 32(6):1213-25. PubMed ID: 24927856
[TBL] [Abstract][Full Text] [Related]
18. Making advances in first-line chronic lymphocytic leukemia treatment.
Wierda WG
J Clin Oncol; 2012 Sep; 30(26):3162-4. PubMed ID: 22869876
[No Abstract] [Full Text] [Related]
19. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Carter SJ; Bernstein SH; Friedberg JW; Barr PM
Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
[No Abstract] [Full Text] [Related]
20. Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.
Kourelis TV; Kahl BS; Benn P; Delach JA; Bilgrami SF
Acta Haematol; 2011; 126(1):40-3. PubMed ID: 21430370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
